TegMine has identified Taiwan’s OBI as a company that can help advance its ambitions. The new deal secures TegMine the right ...

A new paper published in Nature on June 4 shines light on how an enigmatic part of male aging—the loss of Y chromosomes—is ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Startup Clairity scored a green light from the FDA for the agency's first artificial intelligence tool designed to predict ...

Sibeprenlimab targets a protein called A proliferation-inducing ligand (APRIL), and the drug is designed to limit the ...

The widely used cough suppressant dextromethorphan is an NMDA receptor antagonist. Seyltx and Atlanta-based NeurOp are ...

In return for the ex-China rights to its new addition, called velinotamig, Cullinan has agreed to pay Genrix Bio the upfront ...

Protara, hoping to ultimately transition to a commercial stage company, snagged a chief commercial officer in Bill Conkling, ...

Elon Musk's brain-computer interface startup Neuralink secured $650 million in series E funding to expand patient access to ...

Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

As favor in the general market swings away from cell therapy, Immatics’ CEO is choosing to focus on what he can control: ...